Juliana Elstad is the President, CEO of Vibrato Medical. She is a global executive with significant experience identifying opportunities for growth and delivering success in start-ups to multi-billion-dollar companies, and has led innovative medical companies through compelling vision, strategy, and growth. She has worked both in start-ups and Fortune 500 corporations in the U.S. and Emerging Markets and has worn many leadership “hats” in the medical device business.
She serves as a board member of AdvaMed Accel, the world’s largest trade association representing medical device and diagnostics manufacturers. AdvaMed Accel is the division within AdvaMed dedicated to addressing the needs and challenges of smaller innovative medical device and diagnostics manufacturers – the lifeblood of the medical technology industry.
Advamed is powering the MedTech Conference in Anaheim, California, October 9-11, 2023. Featuring world-class speakers, a cross-cutting educational program, invaluable networking and next-level technology, this forum for transformational ideas is a can’t-miss event for the industry’s prominent and most promising companies.
In an ideal world, no one would have a catheter, but the reality is that 100M patients worldwide rely on an indwelling urinary catheter. Catheterized patients often experience problems, such as catheter-associated urinary tract infections (CAUTI), catheter blockages, leaking and bladder spasms. FLUME estimates the healthcare burden of Foley catheter complications to be equivalent to $80 on average, for each of the 28m placed annually in the US – a total burden of around $2.2bn – and close to $60 even for short-term placement.
Join Co-Founder & Chief Executive at The Flume Catheter Company Limited Roger Holmes, and DeviceAlliance MedTech Radio Host Scott Johnson as they discuss…
– The catheter problem impacting 100M people
– The 2.2B burden in the U.S.
– Flume Catheter’s goal to impact millions for a philanthropic purpose
– Roger’s life lessons in entrepreneurship
Creighton ChaneyRoger Holmes: Reaching Across the Pond | Ep.52
In Episode 50, we speak with CEO of nRichDX, William Curtis. nRichDX’s patented IVD-labeled platform is the result of an intensive technology development effort that commenced in 2016 and was commercially launched in November 2019. It’s a patented sample prep system that in its current state already provides up to 10x more genetic targets for liquid biopsy testing. It’s commercial stage with some highly regarded customers that cost-effectively improves test sensitivity, earlier detection and earlier intervention leading to superior outcomes. They have been supporting themselves with some angel money and contracts as they have developed both manual and semi-automated systems and data to support performance. The company is raising $20 mm to (1) develop a fully automated system using the exact same scalable technology and (2) to finally be able to invest in Sales and Marketing and commercialize their products.
Join us as we discuss the $5.53 billion liquid biopsy market, the evolution of early cancer detection, the rising importance for liquid biopsy abilities to find information about cancer diseases with the use of blood samples, William’s MedTech entrepreneurial insights into launching companies tackling today’s unmet clinical needs..
Today we speak with CEO of Diality, Osman Khawar. Diality is a privately held medical device company currently in development of a versatile hemodialysis machine useable at home or in a variety of care settings, including nursing homes, hospitals, transitional care facilities and dialysis centers*. Committed to helping build a future where all patients and partners can control kidney disease, Diality is focused on developing solutions that help care providers improve the care and lives of patients with kidney disease while giving physicians the flexibility to prescribe personalized dialysis treatments regardless of delivery setting.
Join us as we discuss the current status of dialysis treatment, the burdens of treatments, the evolution toward consumer centric dialysis, and how the opportunity for innovation can improve the distinct needs of dialysis providers across all segments of the market.
Ramin Mousavi is the CEO, President, and Board of Directors for Cathworks; a medical technology company focused on applying its advanced computational science platform to optimize Coronary Artery Disease (CAD) therapy decisions and elevate coronary angiography from visual assessment to an objective FFR-based decision-making tool for physicians. Ramin has executive leadership and operational experience
in general management, marketing, strategy, product development, and commercialization across multiple market segments and was responsible for developing the clinical and commercial strategy for CathWorks. He helped with the regulatory clearance of the product in Europe, United States and Japan. He also led the company’s Global Health Economic & Reimbursement strategy where the company was successful in receiving reimbursements in the US and Japan. He is leading the way in building an innovative and community-based organization with a mission to provide clinicians with objective data, so they can make the best decisions for their patients.
Join us as we discuss the unmet clinical needs for coronary artery disease, Cathworks journey to understanding the physician perspective, Ramin’s personal leadership journey, the advancement of computational science, the economic benefits for patients and payers, the evolution of innovation, and much more!
AXIS Research & Technologies, Inc. was an idea that originally started from a non-profit created by Founder and CEO Nick Moran to educate youth about the negative effects of diabetes and being overweight. That nonprofit morphed into a broader opportunity to create a Bio Skills Company to provide facilities, medical equipment and tele-training services for surgeons, medical professionals and medical device companies to practice surgical techniques, develop and perfect medical devices and provide education to audiences worldwide. Now in 2021 AXIS is rapidly creating and deploying new technology and IP that is advancing how medical device companies, hospital systems and researchers develop, evaluate and improve medical procedures, devices and outcomes that are reducing risks, and saving lives.
Join us as we discuss how Axis is helping to solve current Medtech challenges with its medical skills training platform, how it’s state-of-the-art labs across America are allowing surgeons, educators and researchers to impact the training sphere, and much more!
Creighton ChaneyAxis Research & Technologies: Medtech Training Camp | Ep.46
Irvine is home to over 15,000 businesses, and life sciences and medical device companies constitute one of the fastest-growing sectors. With a global focus on the Medtech industry, the need to build an infrastructure that can support the explosive forecasted growth is more crucial than ever. A well-educated, job-ready workforce, world-renowned R&D facilities and community initiatives all conspire to make Irvine a magnet for Medtech success. So how is Irvine executing on their 50-year plan coming out of the pandemic, to ensure our medical device community is not only a hub of talent and innovation for California, but for the world?
In this episode of DeviceAlliance’s Medtech Radio, we speak with the President and CEO at Greater Irvine Chamber of Commerce, Destination Irvine and Irvine Economic Development, Bryan Starr. Join us as we discuss the efforts the Irvine Chamber is making to support the medical device community, their initiatives to attract foreign medical device companies to relocate to Irvine, as how we as a community can engage in local efforts to ensure the thriving success of medical device industry.
Creighton ChaneyBryan Starr: Community Investment in Global Medtech | Ep.44
MD&M West is the nation’s leading advanced Medtech design & manufacturing conference. It brings together Medtech engineers, business leaders, disruptive companies, and innovative thinkers to create powerful solutions and life-changing medical devices. From 3D printing and biomaterials to robotics and digital health, MD&M West is the largest Medtech expo for suppliers and buyers to discover innovation, engineer new technology, and build life-changing medical devices. The event will feature….
Discover the Medtech trends impacting your today and tomorrow on August 10th through 12th, 2021 at the Anaheim Convention Center.
Join us as we speak with the Group Event Director of Informa Markets Engineering, Hayley Haggarty. We discuss MD&M’s new focus on the hub of innovation and new ideas within Medtech, the latest trends in products and technology, the latest Medtech solutions being showcased to address tomorrow’s challenges.
Creighton ChaneyHayley Haggarty: Building A Better World | Ep.42
Such a simple question, and yet it continues to vex popular consultants and laypeople alike. Leadership is a process of social influence, which maximizes the efforts of others, towards the achievement of a goal.
In this episode of DeviceAlliance’s Medtech Radio, we speak with the President of Bioplatte, Thomas Hopson. Thomas Hopson is an accomplished business executive with over 30 years of experience in the medical device industry. Thomas has provided leadership to multi-million-dollar business enterprises in Europe, Asia, and the United States, and he has successfully transformed multiple struggling organizations into healthy and thriving businesses. He joined Bioplate as President in 2018, bringing with him an extensive background in sales, business development, organizational learning, and product commercialization. Before joining Bioplate, Thomas served as the Director, Global Talent Management & Learning at Edwards Life Sciences. Prior to Edwards, Thomas held various leadership positions at St. Jude Medical.
Join us as we discuss his life’s journey into leadership, his most valuables mistakes, keeping teams motivated in times of crisis, how to handle making unpopular decisions, and key trends in key trends in the global craniofacial fixation market.
Creighton ChaneyThomas Hopson: Leadership Built to Last | Ep.41
What are Contract Research Organizations? For any Medtech company, working with CRO’s allow them to outsource work that would otherwise require significant capital to do internally. CRO’s let you avoid buying expensive equipment and hiring or training staff for a short-term project. Having independent oversight is critical to ensuring compliance, keeping your clinical research trial on track and bringing your device to market faster. For this reason, many companies hire a clinical research organization (CRO) to monitor, audit, and even manage their trial. Medical device trials in particular bring complex compliance challenges, so having a CRO with specific expertise in this area can be tremendously beneficial. How can you be sure you hire a medical device CRO that is committed to ensuring compliance and is as invested in your success as you are?
In this episode of DeviceAlliance’s Medtech Radio, we speak with the Director of Regulatory Affairs at Inari Medical, Sarah Boundy Wong and Vice President Clinical Affairs & Market Dev. at JenaValve Technology, Inc., Vinny Podichetty. Join us as we discuss the best-shared practices and methodologies for selecting a medical device CRO, where does one find CROs, the biggest selection considerations, and lessons learned from both of their professional experiences.
Creighton ChaneySarah Boundy Wong & Vinny Podichetty: The CRO Selection Blueprint | Ep.40
